Edgar Filing: SIGA TECHNOLOGIES INC

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)

SIGA Technologies, Inc.
----------------------------
(Name of issuer)

Common Stock, par value $0.0001 per share
---------------------------------------------
(Title of class of securities)

826917-10-6
-----------------
(CUSIP number)

Barry F. Schwartz
35 East 62nd Street
New York, New York 10021
(212) 572-8600
--------------------------
(Name, address and telephone number of person
authorized to receive notices and communications)

October 8, 2003
----------------------------
(Date of event which requires
filing of this statement)

If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box
[ ].

Note: Schedules filed in paper format shall include a signed original
and five copies of the schedule, including all exhibits. See Rule 13d-7 for
other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).

(Continued on following pages)

13D

CUSIP No. 826917-10-6 Page 2 of 16 Pages
-------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS

Mafco Holdings Inc.
-------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
-------------------------------------------------------------------
3. SEC USE ONLY

-------------------------------------------------------------------
4. SOURCE OF FUNDS

WC
-------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) [ ]

-------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
--------------------------------------------------------------------
7. SOLE VOTING POWER
NUMBER OF 0
SHARES --------------------------------------
BENEFICIALLY 8. SHARED VOTING POWER
OWNED BY 5,535,385
EACH --------------------------------------
REPORTING 9. SOLE DISPOSITIVE POWER
PERSON 0
WITH --------------------------------------
10. SHARED DISPOSITIVE POWER
5,535,385
--------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,535,385
--------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[ ]

--------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

25.6%
--------------------------------------------------------------------
14. TYPE OF REPORTING PERSON

CO
--------------------------------------------------------------------

13D

CUSIP No. 826917-10-6 Page 3 of 16 Pages
-------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS

MacAndrews & Forbes Holdings Inc.
-------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
-------------------------------------------------------------------
3. SEC USE ONLY

-------------------------------------------------------------------
4. SOURCE OF FUNDS

AF
-------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) [ ]

-------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION

5,535,385
--------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[ ]

--------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

25.6%
--------------------------------------------------------------------
14. TYPE OF REPORTING PERSON

CO
--------------------------------------------------------------------

13D

CUSIP No. 826917-10-6 Page 4 of 16 Pages
-------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS

TransTech Pharma, Inc.
-------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
-------------------------------------------------------------------
3. SEC USE ONLY

-------------------------------------------------------------------
4. SOURCE OF FUNDS

WC
-------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e) [ ]

-------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
--------------------------------------------------------------------
7. SOLE VOTING POWER
NUMBER OF 5,208,333
SHARES --------------------------------------
BENEFICIALLY 8. SHARED VOTING POWER
OWNED BY 0
EACH --------------------------------------
REPORTING 9. SOLE DISPOSITIVE POWER
PERSON 5,208,333
WITH --------------------------------------
10. SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

5,208,333
--------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
[ ]

--------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

21.8%
--------------------------------------------------------------------
14. TYPE OF REPORTING PERSON

CO
--------------------------------------------------------------------

This statement ("Amendment No. 1") amends and supplements
the statement on Schedule 13D, dated August 13, 2003, filed by Mafco Holdings
Inc., a Delaware corporation ("Mafco"), and MacAndrews & Forbes Holdings Inc.,
a Delaware corporation ("Holdings") (the "Schedule 13D"), relating to the
shares of common stock, par value $0.0001 per share ("Common Stock"), of SIGA
Technologies, Inc., a Delaware corporation (the "Company"). This Amendment No.
1 is being filed by Mafco, Holdings and TransTech Pharma, Inc., a Delaware
corporation ("TransTech"), with respect to shares of Common Stock that may be
deemed to be beneficially owned by the Reporting Persons (as defined below).
The Company has its principal executive offices at 420 Lexington Avenue, Suite
601, New York, New York 10170. Capitalized terms used herein shall have the
meanings ascribed to them in the Schedule 13D unless otherwise defined herein.

Item 2. Identity and Background.
-----------------------

The response to Item 2 is amended by deleting it in its
entirety and substituting the following in lieu thereof:

This statement is being filed by Mafco, Holdings and
TransTech (collectively, the "Reporting Persons") with respect to shares of
Common Stock that may be deemed to be beneficially owned by the Reporting
Persons. Mafco is a holding company whose sole stockholder is Ronald O.
Perelman. Holdings is a holding company and a direct wholly owned subsidiary
of Mafco. TransTech is a corporation in which Mr. Perelman has a direct
ownership interest. Mr. Perelman disclaims beneficial ownership of the
securities deemed to be beneficially owned by TransTech.

The business address of the Reporting Persons (other than
TransTech) is 35 East 62nd Street, New York, New York 10021. The business
address of TransTech is 4170 Mendenhall Oaks Parkway, Suite 110, High Point,
North Carolina 27265.

Schedule I attached hereto sets forth certain additional
information with respect to each director and executive officer of the
Reporting Persons (the "Schedule I Persons") and is incorporated herein by
reference.

To the knowledge of the Reporting Persons, during the last
five years neither the Reporting Persons, nor any of the Schedule I Persons,
nor The Gittis Family Foundation, a charitable foundation referred to in Item
5, (i) has been convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors) or (ii) was a party to a civil proceeding
of a judicial or administrative body of competent jurisdiction and as a result
of such proceeding was or is subject to a judgment, decree or final order
enjoining future violations of, or prohibiting or mandating activities subject
to, federal or state securities laws or finding any violations with respect to
such laws.

Each of the Reporting Persons is a Delaware corporation. All
of the Schedule I Persons are citizens of the United States of America.

Page 5 of 16

Item 3. Source and Amount of Funds or Other Consideration.
-------------------------------------------------

The following is added to the response to Item 3:

On October 14, 2003, following delivery by Holdings and its
assignees of written notice pursuant to the Purchase Agreement on October 8,
2003 (the "Option Exercise Notice"), as more fully described in Item 4 below,
pursuant to the terms of the Purchase Agreement (as modified by the Assignment
Letter Agreement and the TransTech Assignment Letter Agreement (as defined
below)), the Reporting Persons (other than TransTech) acquired certain
securities of the Company for an aggregate purchase price of $2,010,905, which
funds were obtained from cash on hand.

On October 14, 2003, following delivery by Holdings and its
assignees of the Option Exercise Notice, as more fully described in Item 4
below, pursuant to the terms of the Assignment Letter Agreement and the
Purchase Agreement, Barry F. Schwartz, Executive Vice President and General
Counsel of Mafco and Holdings, and Todd J. Slotkin, Executive Vice President
and Chief Financial Officer of Mafco and Holdings and a Director of TransTech,
each acquired certain securities of the Company for a purchase price of
approximately $45,000, which funds were obtained from personal funds.

On October 8, 2003, as more fully described in Item 4 below,
the Reporting Persons exercised their option to purchase additional securities
of the Company for an aggregate amount of $6,840,595, subject to the
conditions described in Item 4 below, which funds (i) Mafco and Holdings
expect to obtain from cash on hand, and (ii) TransTech expects to obtain from
the proceeds of a private placement of its equity securities.

Item 4. Purpose of Transaction.
----------------------

The following is added to the response to Item 4:

On October 8, 2003, the Company, Holdings and TransTech
entered into a Letter Agreement (the "TransTech Assignment Letter Agreement"),
pursuant to which Holdings assigned to TransTech a portion of the Option under
the Purchase Agreement to purchase certain shares of Common Stock and
Warrants. See Item 6.

On October 14, 2003, following delivery by Holdings and
its assignees of the Option Exercise Notice, (A) Holdings acquired from the
Company (x) 1,396,462 shares of Common Stock at a price of $1.44 per share
and (y) a Warrant (the "Tranche B-1 Warrant"), for no additional
consideration, to purchase 698,232 shares of Common Stock, for an aggregate
purchase price of $2,010,905, and (B) Messrs. Schwartz and Slotkin each
purchased (x) 31,250 shares of Common Stock at a price of $1.44 per share
and (y) a Warrant, for no additional consideration, to purchase 15,625
shares of Common Stock, for an aggregate purchase price of $45,000. A copy
of the Option Exercise Notice is attached hereto as Exhibit 13 and a copy
of the Tranche B-1 Warrant is attached hereto as Exhibit 14. The
descriptions of the Option Exercise Notice and the Tranche B-1

Page 6 of 16

Warrant are qualified in their entirety by reference to
the Option Exercise Notice and the Tranche B-1 Warrant, respectively.

In addition, pursuant to the Option Exercise Notice, (A)
Holdings also exercised the remaining portion of its Option to purchase (x)
1,278,191 shares of Common Stock at a price of $1.44 per share and (y) a
Warrant (the "Tranche B-2 Warrant"), for no additional consideration, to
purchase 639,095 shares of Common Stock, for an aggregate purchase price of
$1,840,595, and (B) TransTech exercised the portion of the Option assigned to
it pursuant to the TransTech Assignment Letter Agreement (the "TransTech
Option") to purchase (x) 3,472,222 shares (the "TransTech Shares") of Common
Stock at a price of $1.44 per share and (y) a Warrant (the "TransTech
Warrant"), for no additional consideration, to purchase 1,736,111 shares of
Common Stock, for an aggregate purchase price of $5,000,000. The closing for
the transactions described in this paragraph will only take place following
the approval of the Company's stockholders required by Rule 4350.

The TransTech Assignment Letter Agreement amended the
provision of the Purchase Agreement with respect to the appointment of
individuals to the Board of Directors of the Company to provide that at such
time as Holdings and TransTech have invested an aggregate of $5,000,000 or
more in Common Stock and, with respect to the Holdings Representative (as
defined below), for so long as Holdings, together with its affiliates (other
than TransTech), beneficially owns at least 1,700,000 shares of Common Stock
(as appropriately adjusted for any stock split, combination, reorganization,
recapitalization, reclassification, stock dividend, stock distribution or
similar event), and, with respect to the TransTech Representative (as defined
below), for so long as TransTech, together with its affiliates (other than
Holdings, its officers or affiliates), beneficially owns at least 1,700,000
shares of Common Stock (as appropriately adjusted for any stock split,
combination, reorganization, recapitalization, reclassification, stock
dividend, stock distribution or similar event), the Company will use its
reasonable best efforts to appoint to its Board of Directors one individual
designated by Holdings (the "Holdings Representative") and one individual
designated by TransTech (the "TransTech Representative" and together with the
Holdings Representative, the "Investor Representatives"). The initial Investor
Representatives are to be those individuals that are designated by Holdings or
TransTech, as the case may be, following fulfillment of the conditions
described in this paragraph, and they are to serve until their successors are
duly elected. Thereafter, the Investor Representatives are to be elected at
the same time as other members of the Company's Board of Directors. If for any
reason the Holdings Representative or the TransTech Representative resigns or
is otherwise removed from the Company's Board of Directors, then the Company
will use its reasonable best efforts to appoint, as his or her replacement,
the individual designated by Holdings or TransTech, as the case may be.

Item 5. Interest in Securities of the Issuer.
------------------------------------

The response to Item 5(a) - (b) is amended by deleting the
first, second and fifth paragraphs thereof and substituting the following in
lieu thereof:

Page 7 of 16

Based upon information contained in the Company's Quarterly
Report on Form 10-QSB for the quarter ended June 30, 2003, there were
17,149,682 shares of Common Stock outstanding as of August 13, 2003.

As a result of the transactions described in Item 4, the
Reporting Persons (other than TransTech) may be deemed to share beneficial
ownership of 5,535,385 shares of Common Stock, representing approximately
25.6% of the Common Stock deemed to be outstanding as of October 14, 2003
(which includes certain shares of Common Stock deemed to be beneficially
owned by the Reporting Persons (other than TransTech) but not outstanding).
The Reporting Persons (other than TransTech) have shared power to vote and
dispose of the shares of Common Stock that they own or, in the case of
certain securities, would own upon issuance following the approval of the
Company's stockholders pursuant to Rule 4350, and exercise of the Warrants
held by such Reporting Persons.

In addition, TransTech may be deemed to have beneficial
ownership of 5,208,333 shares of Common Stock, representing approximately
21.8% of the Common Stock deemed to be outstanding as of October 14, 2003
(which includes certain shares of Common Stock deemed to be beneficially owned
by TransTech but not outstanding). TransTech would have sole power to vote and
dispose of such shares of Common Stock upon issuance, following the approval
of the Company's stockholders pursuant to Rule 4350, of the TransTech Shares
and exercise of the TransTech Warrant.

As a result of the transactions described in Item 4, as of
October 14, 2003, Messrs. Schwartz and Slotkin may each be deemed to have
beneficial ownership of 52,083 shares of Common Stock, representing less than
0.3% of the Common Stock deemed to be outstanding (which includes certain
shares of Common Stock deemed to be beneficially owned by Messrs. Schwartz or
Slotkin, as applicable, but not outstanding). Each of Messrs. Schwartz and
Slotkin have sole power to vote and dispose of the shares of Common Stock that
he owns or would own upon exercise of the Warrants described herein.

As of October 14, 2003, although the number of shares of
Common Stock that may be deemed to be beneficially owned by Mr. Drapkin, who
is also a Director of TransTech, remained the same, as a result of the
transactions described in Item 4, his deemed beneficial ownership decreased
from 9.6% to 8.9% of the Common Stock deemed to be outstanding as of such date
(which includes certain shares of Common Stock deemed to be beneficially owned
by Mr. Drapkin but not outstanding).

As of October 14, 2003, although the number of shares of
Common Stock that may be deemed to be beneficially owned by Mr. Gittis
remained the same, as a result of the transactions described in Item 4, his
deemed beneficial ownership decreased from 5.8% to 5.3% of the Common Stock
deemed to be outstanding as of such date (which includes certain shares of
Common Stock deemed to be beneficially owned by Mr. Gittis but not
outstanding).

Page 8 of 16

Based on documents publicly filed, Dr. Eric Rose, a Director
of the Company and TransTech, may be deemed to beneficially own 790,090 shares
of Common Stock, representing approximately 4.1% of the Common Stock deemed to
be outstanding as of October 14, 2003 (which includes certain shares of Common
Stock deemed to be beneficially owned by Dr. Rose but not outstanding). Dr.
Rose holds an aggregate of 101,480 shares of Common Stock and may purchase up
to an aggregate of approximately 688,610 additional shares of Common Stock
pursuant to the May 2001 Investor Warrant, the September 2001 Rose Investor
Warrant and the Rose Options (each as defined below). Dr. Rose has the sole
power to vote and dispose of the shares of Common Stock that he owns or would
own upon exercise of the May 2001 Investor Warrant, the September 2001 Rose
Investor Warrant and Rose Options.

William V. Buccella, Senior Vice President - Legal Affairs
and Secretary of TransTech owns 900 shares of Common Stock, representing less
than 0.1% of the Common Stock deemed to be outstanding as of October 14, 2003.
Mr. Buccella has the sole power to vote and dispose of the shares of Common
Stock that he owns.

Item 6. Contracts, Arrangements, Understandings or Relationships
With Respect to Securities of the Issuer.
----------------------------------------

The following is added to the response to Item 6:

For a discussion of the TransTech Assignment Letter
Agreement and the Option Exercise Notice, see Item 4.

On October 8, 2003, pursuant to the TransTech Assignment
Letter Agreement and the Purchase Agreement, Holdings assigned to TransTech,
and TransTech exercised, the TransTech Option.

A copy of the TransTech Assignment Letter Agreement is
attached hereto as Exhibit 15, a copy of the Assigned Tranche B Warrant held
by Mr. Schwartz is attached hereto as Exhibit 16 and a copy of the Assigned
Tranche B Warrant held by Mr. Slotkin is attached hereto as Exhibit 17. The
descriptions of the TransTech Assignment Letter Agreement, the Assigned
Tranche B Warrant held by Mr. Schwartz and the Assigned Tranche B Warrant held
by Mr. Slotkin are qualified in their entirety by reference to the TransTech
Assignment Letter Agreement, the Assigned Tranche B Warrant held by Mr.
Schwartz and the Assigned Tranche B Warrant held by Mr. Slotkin, respectively.

Dr. Rose holds a warrant to purchase up to 50,000 shares of
Common Stock (the "May 2001 Investor Warrant"). The May 2001 Investor Warrant
is exercisable for a period of seven years at an exercise price of $2.94 per
share. The May 2001 Investor Warrant provides that, with certain limited
exceptions, it is not exercisable if, as a result of such exercise, the number
of shares of Common Stock beneficially owned by the holder thereof and its
affiliates (other than shares of Common Stock which may be deemed beneficially
owned through the ownership of the unexercised portion of such warrant) would
exceed 9.99% of the outstanding shares of Common Stock (the "9.99%

Page 9 of 16

Limit"). Dr. Rose also holds a warrant to purchase up to 38,610 shares of
Common Stock (the "September 2001 Rose Investor Warrant"). The September 2001
Rose Investor Warrant is exercisable for a period of seven years at an
exercise price of $3.552 per share and contains provisions analogous to the
9.99% Limit described above; provided, however, that the 9.99% Limit shall not
apply (i) during the existence of a tender offer for the Rose Common Stock or
(ii) at the option of Dr. Rose, on at least 65 days' advance written notice,
with respect to the September 2001 Rose Investor Warrant. In addition, Dr.
Rose holds options (the "Rose Options") pursuant to the Company's Amended and
Restated 1996 Incentive and Non-Qualified Stock Option Plan, dated August 15,
2001, to purchase 600,000 shares of Common Stock at an exercise price of $2.50
per share.

The form of the May 2001 Investor Warrant is attached hereto
as Exhibit 18 and the form of the September 2001 Rose Investor Warrant is
attached hereto as Exhibit 19. The descriptions of the May 2001 Investor
Warrant and the September 2001 Rose Investor Warrant are qualified in their
entirety by reference to the form of the May 2001 Investor Warrant and the
form of the September 2001 Rose Investor Warrant, respectively.

Item 7. Material to be Filed as Exhibits.
--------------------------------

Exhibit 1 is amended and restated in its entirety and
Exhibits 13 through 19 are added to the response to Item 7.

Exhibit 1 Amended and Restated Agreement of Joint
Filing of Schedule 13D (filed herewith).

Exhibit 13 Option Exercise Notice dated October 8,
2003 (filed herewith).

Exhibit 14 Tranche B-1 Common Stock Purchase Warrant
(filed herewith).

Exhibit 15 Letter Agreement, by and among the
Company, Holdings and TransTech, dated
October 8, 2003 (incorporated by reference
to Exhibit 10(ggg) to the Current Report
on Form 8-K, filed by the Company on
October 9, 2003).

Exhibit 16 Tranche B Common Stock Purchase Warrant
held by Barry F. Schwartz (filed
herewith).

Exhibit 17 Tranche B Common Stock Purchase Warrant
held by Todd J. Slotkin (filed herewith).

Page 10 of 16

Exhibit 18 Form of May 2001 Investor Warrant held by
Dr. Eric Rose (incorporated by reference
to Exhibit L to Amendment No. 2 to the
Schedule 13D filed by Donald G. Drapkin on
June 4, 2001).

Exhibit 19 Form of September 2001 Investor Warrant
held by Dr. Eric Rose (incorporated
by reference to Exhibit R to Amendment No.
4 to the Schedule 13D filed by Donald G.
Drapkin on October 3, 2001).

Page 11 of 16

SIGNATURES
----------

After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information in this statement is true, complete and
correct.

Dated: October 14, 2003

MAFCO HOLDINGS INC.
MACANDREWS & FORBES HOLDINGS INC.

By: /s/ Barry F. Schwartz
--------------------------------
Name: Barry F. Schwartz
Title: Executive Vice President
and General Counsel

Dated: October 14, 2003

TRANSTECH PHARMA, INC.

By: /s/ William V. Buccella
--------------------------------
Name: William V. Buccella
Title: Senior Vice President -
Legal Affairs and
Secretary

Page 12 of 16

AMENDED AND RESTATED SCHEDULE I

DIRECTORS AND EXECUTIVE OFFICERS
OF MAFCO HOLDINGS INC., MACANDREWS & FORBES HOLDINGS INC. AND
TRANSTECH PHARMA, INC.

The name, business address, present principal occupation or
employment, and the name, principal business and address of any corporation or
other organization in which such employment is conducted, of each of the
directors and executive officers of Mafco Holdings Inc., MacAndrews & Forbes
Holdings Inc. and TransTech Pharma, Inc. are set forth below. If no business
address is given for a director or officer of Mafco Holdings Inc. or
MacAndrews & Forbes Holdings Inc., the director's or officer's address is
Mafco Holdings Inc., 35 East 62nd Street, New York, New York 10021. If no
business address is given for a director or officer of TransTech Pharma, Inc.,
the director's or officer's address is TransTech Pharma, Inc., 4170 Mendenhall
Oaks Parkway, Suite 110, High Point, North Carolina 27265.

MAFCO HOLDINGS INC.

Name and Position
(if different from
Principal Occupation Present Principal Occupation or
or Employment) Employment and Address
------------- ----------------------

Ronald O. Perelman Director, Chairman and Chief Executive Officer of Mafco
Holdings Inc.

Donald G. Drapkin Director and Vice Chairman of Mafco Holdings Inc.

Howard Gittis Director and Vice Chairman of Mafco Holdings Inc.

Barry F. Schwartz Executive Vice President and General Counsel of Mafco
Holdings Inc.

Todd J. Slotkin Executive Vice President and Chief Financial Officer of
Mafco Holdings Inc.

Page 13 of 16

MACANDREWS & FORBES HOLDINGS INC.

Name and Position
(if different from Present Principal Occupation or
Principal Employment) Employment and Address
--------------------- ----------------------

Ronald O. Perelman Director, Chairman and
Director, Chairman and Chief Executive Officer of
Chief Executive Officer Mafco Holdings Inc.

Donald G. Drapkin Director and Vice Chairman of Mafco
Director and Vice Chairman Holdings Inc.

Howard Gittis Director and Vice Chairman of Mafco
Director and Vice Chairman Holdings Inc.

Barry F. Schwartz Executive Vice President and
Executive Vice President and General Counsel of Mafco
General Counsel Holdings Inc.

Todd J. Slotkin Executive Vice President and
Executive Vice President Chief Financial Officer of
and Chief Financial Officer Mafco Holdings Inc.

Page 14 of 16

TRANSTECH PHARMA, INC.

Name and Position
(if different from Present Principal Occupation or
Principal Employment) Employment and Address
--------------------- ----------------------

Adnan M. M. Mjalli, Ph.D. Director, President and Chief Executive Officer

Eric Rose, M.D. Valentine Mott/Johnson and Johnson Professor and
Director Chairman of the Department of Surgery at Columbia
University and Surgeon-in-Chief of The Presbyterian
Hospital

Donald G. Drapkin Director and Vice Chairman of Mafco
Director Holdings Inc.

Todd J. Slotkin Executive Vice President and Chief Financial Officer
Director of Mafco Holdings Inc.

Nehad Baker President and Chief Executive Officer of Baker Trading
Director Company

William V. Buccella Senior Vice President - Legal Affairs and Secretary

Stephen L. Holcomb Senior Vice President - Chief Financial Officer and
Treasurer

Stephen J. Ireland Senior Vice President - Business Development

Page 15 of 16

Exhibit Index

Exhibit 1 is amended and restated in its entirety and
Exhibits 13 through 19 are added to the response to the Exhibit Index as
follows:

Exhibit Document
------- --------

1 Amended and Restated Agreement of Joint Filing of Schedule
13D (filed herewith).

13 Option Exercise Notice dated October 8, 2003 (filed
herewith).

14 Tranche B-1 Common Stock Purchase Warrant (filed herewith).

15 Letter Agreement, by and among the Company, Holdings and
TransTech, dated October 8, 2003 (incorporated by
reference to Exhibit 10(ggg) to the Current Report
on Form 8-K, filed by the Company on October 9, 2003).

16 Tranche B Common Stock Purchase Warrant held by Barry F.
Schwartz (filed herewith).

17 Tranche B Common Stock Purchase Warrant held by Todd J.
Slotkin (filed herewith).

18 Form of May 2001 Investor Warrant held by Dr. Eric Rose
(incorporated by reference to Exhibit L to Amendment No. 2
to the Schedule 13D filed by Donald G. Drapkin on June 4,
2001).

19 Form of September 2001 Investor Warrant held by Dr. Eric
Rose (incorporated by reference to Exhibit R to Amendment
No. 4 to the Schedule 13D filed by Donald G. Drapkin on
October 3, 2001).